Anti-CD20 agent has been proposed as a rescue therapy for refractory nephrotic syndrome(NS) on the basis of favorable clinical observations. Yet the long-term effect on maintaining remission or the likelihood of becoming rituximab-dependent is unclear and the information on the safety profile of rituximab is limited. This trial was designed to investigate the safety and efficacy of Rituximab in children with refractory NS.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
The remission rate of steroid-resistant nephrotic syndrome patients after rituximab treatment
Timeframe: within 6 months from the initiation of treatment
The rate of maintaining remission in steroid-dependent nephrotic syndrome patients
Timeframe: within 6 months from the initiation of treatment versus placebo control